Insights and genetic features of extended-spectrum beta-lactamase producing *Escherichia coli* isolates from two hospitals in Ghana

Samiratu Mahazu1,2, Wakana Sato3, Alafate Ayibieke1, Isaac Prah1,3, Takaya Hayashi3, Toshihiko Suzuki4, Shiroh Iwanaga2, Anthony Ablordey5* & Ryoichi Saito1*

Recently, the emergence and rapid dissemination of extended-spectrum beta-lactamase (ESBL)-producing bacteria, particularly of the family Enterobacteriaceae, has posed serious healthcare challenges. Here, we determined the antimicrobial susceptibility and genetic characteristics of 164 *Escherichia coli* strains isolated from infected patients in two hospitals in Ghana. In total, 102 cefotaxime-resistant isolates (62.2%) were identified as ESBL-producers. Multilocus sequence typing of the ESBL-producers identified 20 different sequence types (STs) with ST131 (n = 25, 24.5%) as the dominant group. Other detected STs included ST410 (n = 21, 20.6%) and ST617 (n = 19, 18.6%). All identified ESBL-producers harbored *bla*$_{CTX-M-14}$, *bla*$_{CTX-M-15}$, or *bla*$_{CTX-M-27}$, with *bla*$_{CTX-M-15}$ (n = 96, 94.1%) being the most predominant ESBL allele. Further analysis showed that the immediate genetic environment around *bla*$_{CTX-M-15}$ is conserved within *bla*$_{CTX-M-15}$ containing strains. Five of the 25 ST131 isolates were clustered with clade A, one with sub-clade C1, and 19 with the dominant sub-clade C2. The results show that fluoroquinolone-resistant, *bla*$_{CTX-M-14}$- and *bla*$_{CTX-M-15}$-producing ESBL *E. coli* ST131 strains belonging to clade A and sub-clades C1 and C2 are disseminating in Ghanaian hospitals. To the best of our knowledge, this is the first report of the ST131 phylogeny in Ghana.

Beta-lactam antimicrobials have been used extensively in healthcare settings and animal husbandry to treat bacterial infections. The spread of extended-spectrum β-lactamase (ESBL)-producing *Escherichia coli*, such as the high-risk clone ST131, has resulted in a global surge in the number of ESBL-producing *E. coli* strains after their first identification in 1983 in Germany1,2. *Escherichia coli* ST131 is a pandemic strain responsible for numerous cases of recurrent urinary tract infections and sepsis3. Following its first identification in 2008, ST131 has attained global dominance, possibly primed by the sequential acquisition of certain virulence factors and antibiotic-resistant determinants4–6. Proliferation of this pathogenic clone was demonstrated to be driven by a single subclone, H307,8, also named clade C, which carries genes encoding the type 1 fimbriae adhesin. Given its multidrug resistance and association with ESBLs, ST131 is an urgent public health concern. Recently, resistance to carbapenems and colistin in ST131 clones was reported9–11. This phenomenon reduces therapeutic options, as these are last-resort antibiotics11. Cefotaximase-15 beta-lactamase (*bla*$_{CTX-M-15}$) is widely disseminated and is the most frequently identified ESBL allele in ST13112. Phylogenetically, ST131 is classified into three clades, A, B, and C. Clade A is the most divergent, antibiotic-sensitive clade associated with *fimH41* and differs from B and C by approximately 7000 and 8900 single-nucleotide polymorphisms (SNPs), respectively4,7,13. Clade B, known to be involved in human-to-animal transmission, is typically fluoroquinolone-susceptible and differs from clade C by 70 nucleotide substitutions; and is identified primarily by *fimH2214*. The evolution of clade C was reported to coincide with the introduction and clinical use of fluoroquinolones (FQs) in the mid-1980s15. Strains in clade C possess FQ alleles

1Department of Molecular Microbiology, Tokyo Medical and Dental University, Tokyo, Japan. 2Department of Environmental Parasitology, Tokyo Medical and Dental University, Tokyo, Japan. 3Department of Molecular Virology, Tokyo Medical and Dental University, Tokyo, Japan. 4Department of Bacterial Pathogenesis, Tokyo Medical and Dental University, Tokyo, Japan. 5Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana. *email: aablordey@noguchi.ug.edu; r-saito.mi@tmd.ac.jp
that are consistent with their FQ-resistant phenotype. Clade C also appears to be the most dominant group expressing the *fim*H30 allele. This clade was further divided into nested sub-lineages C1/H30R and C2/H30Rx. C1/H30R is often associated with *bla*CTX-M-14/*bla*CTX-M-27, and C2/H30Rx is associated with *bla*CTX-M-15-type ESBLs, with the ESBL alleles typically carried on IncF plasmids.

Previous studies demonstrated that other hypervirulent STs have not attained the same global prominence as ST131; however, the unique traits responsible for the global dissemination of ST131 remain unclear. Although several studies have reported on the phylogeny of ST131 globally, data on ST131 in Ghana is scanty. Here we characterized 25 ST131 isolates from Ghana by whole genome sequencing. We investigated their genetic features and phylogenetic relationship with other globally described ST131 strains.

**Results**

**Antibiotic susceptibility profiles and characterization of ESBLs.** Overall, *E. coli* isolates showed varying proportions of resistance to the antibiotics against which they were tested. The resistance ranged from 1.83% (amikacin) to 87.8% (sulfamethoxazole trimethoprim). Among the isolates, 104 (63.4%), 102 (62.2%), and 108 (65.9%) were resistant to levofloxacin, cefotaxime, and ciprofloxacin, respectively. The rates of antibiotic resistance, MIC_{50}, MIC_{90}, and ranges of all isolates are shown in Table 1. All 102 (62.2%) CTX-resistant *E. coli* isolates were ESBL-producers; among them, 96 (94.1%) harbored *bla*CTX-M-15, five had *bla*CTX-M-14, and one had *bla*CTX-M-27. Among the 102 ESBL-producers, 90 (88.2%) had co-resistance to either ciprofloxacin or levofloxacin. Double mutations, serine 83 to leucine (S83L) and aspartic acid 87 to asparagine (D87N), were observed in the GyrA regions of 19 isolates, and the single mutation S83L was detected in the GyrA region of five *fim*H41 isolates, four of which carried *bla*CTX-M-14-ESBL (Supplementary data S1). All *bla*CTX-M-15 isolates with double mutations were associated with elevated MICs for fluoroquinolones, and especially ciprofloxacin (> 8 µg/mL), compared to the relatively low MICs (1 µg/mL) of fluoroquinolones for the *fim*H41, *bla*CTX-M-14 ESBL strains (Supplementary data S2) with single mutations.

| Antimicrobial agents          | Breakpoint for resistance (µg/mL) | % resistance | MIC (µg/mL) | Range | MIC_{50} | MIC_{90} |
|------------------------------|----------------------------------|--------------|-------------|-------|----------|----------|
| Piperacillin                 | ≥ 128                            | 86.0         | 1–64        | >64   | >64      |          |
| Cefazolin                    | ≥ 8                              | 72.0         | 1–16        | >16   | >16      |          |
| Cefotaxime                   | ≥ 4                              | 62.2         | ≤0.5–32     | 32    | >32      |          |
| Cefazidime                   | ≥ 16                             | 48.8         | ≤0.5–16     | 8     | >16      |          |
| Ceferpine                    | ≥ 16                             | 50.6         | ≤0.5–16     | 16    | >16      |          |
| Sulbactam/ampicillin         | ≥16/32                           | 40.9         | ≤2/4–8/16   | 8/16  | >8/16    |          |
| Cefpodoxime                  | ≥ 8                              | 62.2         | ≤1–4        | >4    | >4       |          |
| Aztreonam                    | ≥ 16                             | 57.3         | ≤0.5–16     | 16    | >16      |          |
| Imipenem                     | ≥ 4                              | 0.0          | ≤0.25–2     | ≤0.25 | ≤0.25    |          |
| Meropenem                    | ≥ 4                              | 0.0          | ≤0.25–1     | ≤0.25 | ≤0.25    |          |
| Gentamicin                   | ≥ 16                             | 39.0         | ≤0.25–8     | 1     | >8       |          |
| Amikacin                     | ≥ 64                             | 1.83         | ≤1–32       | 4     | 16       |          |
| Minocycline                  | ≥ 16                             | 42.1         | 0.5–8       | 8     | >8       |          |
| Fosfomycin                   | ≥ 256                            | 0.0          | ≤32–64      | ≤32   | ≤32      |          |
| Sulfamethoxazole/trimethoprim| ≥76/4                            | 87.8         | ≤9.5/0.5–38/2| >38/2 | >38/2    |          |
| Levofloxacin                 | ≥ 2                             | 63.4         | ≤0.25–4     | >4    | >4       |          |
| Cefmetazol                   | ≥ 64                             | 2.4          | ≤0.5–128    | 2     | 8        |          |
| Ciprofloxacin                | ≥ 1                             | 65.9         | ≤0.25–8     | >8    | >8       |          |

Table 1. Minimum inhibitory concentration 50 (MIC_{50}) and Minimum inhibitory concentration 90 (MIC_{90}) values and antibiotics resistance percentage values of 164 *E. coli* isolates.

**STs and fimH alleles.** The 102 ESBL-producers were classified into 20 sequence types (STs; Fig. 1). *E. coli* ST131 was predominant (n = 24, 23.5%), followed by ST410 (n = 21, 20.6%) and ST617 (n = 19, 18.6%). These three STs accounted for approximately three-fifths of the total number of ESBL-producers. Strains identified as ST131 showed high (100%) resistance rate to ciprofloxacin and were co-resistant to other antibiotics (Table 2). Among ST131 strains, we also observed that the fimH30-associated strains exhibited high resistance to antibiotics compared to the fimH41-bearing strains. However, considering reports about antibiotic sensitivity of fimH41 strains, it is important to note that fimH41 strains showed 80% resistance to five antibiotics (Fig. 2). From the initial ST131 PCR screening, one non-ESBL and 24 ESBL isolates belonged to ST131. This non-ESBL producing isolate, also showed low-level resistance (MIC 1 µg/mL) to ciprofloxacin. Considering that ST131 strains are associated with fluoroquinolone resistance, we included this non-ESBL strain in subsequent analysis after MLST confirmed that it was ST131, to compare ESBLs and non-ESBLs among ST131 strains. The *fim*H30 allele
(n = 19, 76%) was the most common fimH type detected in 19 of 25 E. coli ST131 isolates. This was followed by fimH41 (n = 5, 20%) and fimH99 (n = 1, 4%). Four of the five isolates with fimH41 among ST131 harbored blaCTX-M-14.

**Pangenome and phylogenetic analysis.** An analysis of 25 ST131 isolates identified 7700 genes with 3926 core genes, 110 soft core genes in 95–99% of isolates, 1639 shell genes in 15–95%, and 2025 cloud genes in 15% of isolates. The genome sequence of the 25 strains were mapped onto that of reference strain EC958.
A maximum likelihood tree was built on 1037 core genome SNP alignment. The strains were clustered into two major groups, the \textit{fimH41}-associated group composed of five strains, and a \textit{fimH30} group with 20 strains (Fig. 3). In silico antibiotic resistance gene profiling showed that most isolates contained multiple resistance genes (Supplementary data S1, Fig. 3).

The plasmid replicon type \textit{IncFIB} was the most common \textit{IncF}-type plasmid, found in 21 (84.0\%) isolates, followed by \textit{IncFIA} 19 (76.0\%) and \textit{IncFII} 8 (32\%). \textit{IncQ1} was detected in three (12.0\%) isolates. \textit{IncN} was assigned to one (4.0\%) isolate (Supplementary data S1).

An analysis of 25 \textit{ST131} and 86 global \textit{ST131} isolates identified 11,942 genes. There were 3705 core genes in 99–100\% of the isolates, 193 soft core genes in 95–99\%, 1583 shell genes in 15–95\%, and 6461 cloud genes in 15\% of the isolates. Among the global collection of 86 isolates, 24 were isolated in the United States (US), 13 from the United Kingdom (UK), 13 from Germany, six from the Democratic Republic of Congo (DR Congo), four from Denmark, four from Spain, three from Japan, three from Australia, two from Tanzania, two from Ireland, two from Thailand, two from Canada, one from Portugal, one from Laos, one from Vietnam, one from the Netherlands, and one from Nepal. There was no information on the geographical locations of three isolates.

All 86 isolates, together with the 25 isolates from Ghana, classified into six \textit{ST131} subclades, A, B0, B, C0, C1, and C2. The dominant subclade observed was C2. Nineteen of the Ghana isolates clustered with strains from various geographic regions in clade C2. One isolate clustered with other strains in clade C1 and five clustered with strains in clade A. None of our isolates clustered with others in C0, B, and B0. Some clustered closely with strains from the US, Ireland, Spain, the UK, Germany, and Australia. Notably, although the strains from other African countries (Democratic Republic of Congo, Tanzania) clustered among the C2 group, none clustered closely with our Ghanaian isolates (Fig. 4).

**Genetic environment of \textit{bla}_{CTX-M-15}.** \textit{bla}_{CTX-M-15} was found on a 167,739 bp length \textit{IncFII} plasmid pEc55\_1 (accession no. CP059131.1) in strain EC55, flanked by intact \textit{ISEcP}1 with 48 bp spacer upstream and an open reading frame 477 (ORF477) which encodes tryptophan synthase, with a 46 bp spacer downstream. This structural arrangement was observed in strains Ec1494 and the 162,792 bp plasmid pS802-CTX-M. However, \textit{bla}_{CTX-M-15} was found on a 3,015,999 bp length in Ec1494, suggesting \textit{bla}_{CTX-M-15} may have been integrated into the chromosome of Ec1494. In pEc55\_1 and pS802-CTX-M, these were also flanked by two partial \textit{Tn2} transposons truncated by two complete, \textit{IS26} insertion sequences further upstream and downstream of \textit{bla}_{CTX-M-15}. The partial \textit{Tn2} is truncated by a gene belonging to the \textit{bla}_{TEM} family in pS802-CTX-M, while a \textit{bla}_{OXA} gene, which might have been mobilized by an adjacent \textit{IS26}, was found lying downstream of \textit{bla}_{CTX-M-15} between two \textit{IS26} insertion sequences in pEC55\_1. Compared to pEC55\_1 and pS802-CTX-M, a partial \textit{Tn2} was found only downstream of \textit{bla}_{CTX-M-15} in Ec1494 (Fig. 5).
Discussion

Our study provides information on the epidemiology, antibiotic resistance, and phylogenetic relationships among ST131 isolates from Ghana. We documented the highest rate of resistance to sulfamethoxazole trimethoprim. This rate was relatively higher than that reported (78.4%) by Freeman et al., also in Ghana21, and comparably lower than that reported in a Nigerian study, in which more than 90% of the isolates were resistant to trimethoprim sulfamethoxazole22. Recent studies in Ghana show that antibiotics are heavily abused in Ghanaian communities and among tertiary students. The research disclosed that individuals who engaged in this practice resort to self-medication partly, as a result of financial constraints, as most could barely afford the cost of proper medical care, even when they have knowledge of the implications; moreover, some of these individuals fail to complete the full course of their antibiotic treatment23,24. Additionally, data from previous studies show that antibiotics are prescribed and dispensed particularly in the rural areas of Ghana by unauthorized personnel23,24. The consequences of such practices are the observed clinical resistance to antibiotics and treatment failure due to selective pressure. In light of this, more stringent measures need to be instituted to regulate prescriptions and the usage of antibiotics in Ghana.

More than half of the isolates were frequently resistant to third-generation cephalosporin, cefpodoxime (62.2%), whereas 48.8% were resistant to cefazidime. A study of the antibiotic prescription rate in Ghana revealed that cephalosporins are highly prescribed because of the availability of inexpensive generic forms that are covered by the National Health Insurance Scheme (NHIS) in Ghana25. Cephalosporins are also preferred for empirical therapy because of their minimal toxicity25. The extensive use and high resistance rate of these antimicrobial agents can result in a serious therapeutic challenge in the future if left unchecked.

In most laboratories, cefotaxime is broadly used to identify ESBL-producing isolates26. Here, 102 (62.2%) isolates were resistant to cefotaxime. These harbored $bla_{CTX-M-14}$, $bla_{CTX-M-15}$, or $bla_{CTX-M-27}$. Consequently, the observed resistance is likely attributed to the presence of $bla_{CTX-M}$ genes. All isolates in our collection were susceptible to fosfomycin, meropenem, and imipenem. These medicines are costly, not covered by the NHIS in Ghana, and are used to treat serious infections; therefore, their prescription rate is extremely low25 and this might explain the 100% susceptibility observed in this study.

More than half (62.2%) of the isolates were ESBL-producers, contradictory to the relatively low prevalence (16.1%) among 143 extraintestinal pathogenic (ExPEC) strains in a Tanzanian study27, where, the majority (128) of the patients were pregnant women and 15 children. The results also showed that ESBL production was significantly increased in children than in the pregnant women, possibly resulting from hospital-acquired bloodstream infections among the children. Much of the difference between the ESBL prevalence in both studies could be due to the patient group involved, which also points to the possible dissemination of ESBL strains in hospital settings and the need to implement robust systems to control the situation. Another study28 in Ghana detected 62% of ESBL-producing isolates, similar to the result from this study. This high occurrence of ESBLs among clinical isolates is of concern as it is likely to result in reliance on last line antibiotics for treatment and
the development of new antibiotics may not keep pace with development of resistance in bacteria, plunging us into a post-antibiotic era29.

Most ESBL-producing *E. coli* have FQ resistance, through chromosomal mutations of FQ-target sites30–32. Like previously reported results for FQ resistance, we found that multiple substitutions in target sites cause high-level ciprofloxacin resistance among *bla*CTX-M-producing *E. coli*. *E. coli* ST131 is a global pandemic clone, and clade C2/fimH30-Rx, in particular, is known to be highly virulent15,33,34. In this study, although the *bla*CTX-M-producers were diverse, *E. coli* ST131 was the prime genotype among FQ-resistant, *bla*CTX-M-producing *E. coli*, similar to previous reports from Ghana35 and Nigeria36. Specifically, the fimH30-Rx clone appears to have spread widely in Ghanaian hospitals, as it has in many different regions worldwide34. The prevalence of ST131 (23.5%) among

**Figure 4.** Rooted maximum-likelihood phylogenetic tree of 25 *Escherichia coli* ST131 and 86 *E. coli* ST131 representing the global collection. The phylogenetic tree was built based on 2656 core genome SNPs alignment. Branch patterns were assessed by 1000 bootstrap replicates. Bootstrap support values are shown from 70 (minimum) to 100 (maximum). Clades A, B0, B, C0, C1, and C2 are represented by strips colored lemon green, turquoise, orange, light green, pink, and blue, respectively. The year and country of isolation are displayed in assorted colored strips. Allelic profiling data are shown as color strips from inside out as the ESBL type, GyrA, ParC, and fim type. Accession numbers and IDs of the strains are labeled at the tips. Figure was visualized and annotated with iTOL v5 (https://itol.embl.de/personal_page.cgi).
ESBL-producing *E. coli* was comparable to the 20.5% in a study in Europe\(^3\); but lower than the prevalence from human isolates (52%) in a Canadian study\(^4\). The differences in ST131 prevalence among countries has been attributed to factors such as the antibiotic consumption rate and dietary habits\(^2\). This study also reports a high number of FQ-R *blaCTX-M-15* producing ST410 and ST617 strains. ST410 has been recently described as a high-risk clone with multi-drug resistance like ST131, coupled with a wide host range\(^1\). Also, ST410 comprises ESBL and carbapenem-resistant strains, as has been reported of the globally disseminated NDM-positive *E. coli* strains of ST617\(^1\). The detection of such high-risk clones heightens the need for regular monitoring of drug-resistant clones.

Among the CTX-M-type genes of ESBL-producing *E. coli*, *blaCTX-M-15* and *blaCTX-M-14* are the predominant subtypes worldwide; however, data on the prevalence of these genes in Ghana are limited. The results show that *blaCTX-M-15* is the most widely disseminated CTX-M-type genes in Ghana among ESBL-producing *E. coli*, which agrees with previously published data\(^2,4\). SNP-based phylogenetic analysis grouped the 25 isolates into two major groups corresponding with their *fim* types. Strains with *fimH* alleles, otherwise known as clade A isolates, formed a distinct cluster from the *fimH* isolates. A limitation of this study is that isolates were collected from only two hospitals, one of which is a teaching hospital. We could not get information on the clinical diagnosis and specimens from which some of the isolates were recovered. Analysis of such data would have added to current knowledge on the dissemination of resistant strains.

Phylogenetic analysis clustered the Ghanaian strains closely with some international strains, and most (19/25) belonged to clade C2, a few (5/25) belonged to clade A, and one belonged to clade C1. This shows the extent to which clade C, particularly C2, is disseminated worldwide. All clade C isolates were also characterized as *fimH* isolates. All five clade A isolates had *fimH*41. The association among these *fim* types suggests that the clades are defined by their *fim* types.

In bacteria, the plasmid-mediated transfer of drug-resistance determinants widely contributes to the dissemination of antimicrobial resistance\(^2\). IncFII particularly is suggested to have played a central role in the emergence of C2/H20Rx clade of the ST131\(^1,9\). The results showed that *E. coli* ST131 isolates harbored plasmids predominantly with replicon type F. This is noteworthy and reinforces the pivotal role of IncF plasmids in the dissemination of antibiotic resistance in Enterobacteriaceae. The results also corroborate the findings of other studies in which IncF plasmids were frequently recovered from *E. coli* isolates\(^1,4\). IncF replicon detection also agreed with the results of other reports from Tanzania based on a study where plasmids were detected in *E. coli* isolates from drinking water sources\(^4\) and a study from Nigeria detecting *E. coli* isolates from humans and bovine sources\(^4\). All isolates studied harbored IncF plasmids carrying the ESBL genes *blaCTX-M-15* or *blaCTX-M-14*. There is a postulation that a fluoroquinolone resistant C1 strain obtained ancestral IncFII plasmid and eventually integrated a *blaCTX-M-15* transposition unit, which has been incorporated into the chromosome through transpositional events and recombination within the C2/H30Rx clade\(^1\).

In agreement with other studies\(^4\), IncFIB, 21 (84.0%) was the most identified replicon type and was almost always associated with *blaCTX-M-15* followed by IncFIA (76.0%) and IncFII (32.0%). These results follow the same pattern reported by other authors\(^2\) for *E. coli* isolates. Previous studies reported *blaCTX-M-15* as part of a 2971 bp transposition unit typically found 48 bp to the right of the inverted repeat side of ISEcp1 with a partial ORF (ORF477), and this transposition unit is inserted in Tn2\(^4\). The extent to which *blaCTX-M* genes are expressed have also been shown to be highly dependent on the length of the spacer sequence between ISEcp1 and the start codon of *blaCTX-M* genes\(^4\). Notably, in the isolates investigated, ISEcp1 was found 48 bp upstream of *blaCTX-M-15*. This

---

**Figure 5.** Comparison of the genetic environment of *blaCTX-M-15*. Arrows depict the genes and sequences upstream and downstream of *blaCTX-M-15* in their transcriptional directions as detected by sequencing. The structure of pS802-CTX-M was reversed to enable easy comparison. Shaded regions indicate regions that are common to all isolates. Figure was created and visualized with Easyfig v2.2.2 (https://mjsull.github.io/Easyfig/files.html).
arrangement has also been reported in studies in France, Canada, Italy, the UK, and Spain. IS and SEps1 has also been reported in several countries worldwide. IS and SEps1 belongs to the insertion sequence family IS1380 and has been established as one of several factors involved in mobilizing blaCTX-M genes. Transposon sequences in the pEC55_1 were disrupted by IS26 upstream and downstream of blaCTX-M genes. This association shows the magnitude of the impact of IS26 on shaping antibiotic resistance regions in gram-negative bacteria. According to the results of previous studies, the minimum inhibitory concentrations of cefepime and ceftazidime in isolates with blaCTX-M preceded by IS26 is higher than those in isolates without IS26.

Conclusion
A comparative analysis was used to describe the genetic features of 164 E. coli isolates from two hospitals in Ghana. A high percentage (62%) of the isolates was found to produce ESBL, and these were classified into 20 MLST STs. The pandemic clone ST131 was the dominant ST found. This study also reports a conserved genetic environment for the most prevalent blaCTX-M gene, whether plasmid associated or chromosomal. Phylogenetic analysis revealed that our isolates and other African isolates clustered together with other international strains among clades C, and particularly C2 and A, indicating that same ST131 clone is disseminating worldwide. The detection of FQ-resistant ESBL-producing ST131 shows that ST131 might be circulating in hospitals in Ghana and calls for constant monitoring to control the spread of this highly pathogenic clone. To the best of our knowledge, this is the first report of ST131 that details a SNP-based core genome phylogeny and appraises the epidemiology of its clades and subclades in Ghana.

Materials and methods
Ethical consideration. The Institutional Review Board of the Noguchi Memorial Institute for Medical Research, University of Ghana (FWA0001824) and the Faculty of Medicine, Tokyo Medical and Dental University (M2017-208) reviewed and approved all protocols for this study. Written informed consent was obtained from all participants of the study. All experiments were performed in accordance with the relevant guidelines and regulations.

Bacterial isolation and identification. In total, 164 non-duplicate E. coli isolates recovered from clinical specimens of urine (n = 77), high-vaginal swab HVS (n = 20), wound swabs (n = 11), sputum (n = 9), stool (n = 3), ascitic fluid (n = 1), an ear swab (n = 1), pus (n = 1), urethral discharge (n = 1), and others (n = 34) were obtained from the Effia Nkwanta Regional Hospital and Tamale Teaching Hospital between March 2015 and April 2016. The isolates were stored in 10% skimmed milk at −80°C prior to testing and were identified using a MALDI Biotyper (Bruker Daltonics, Billerica, MA) and VITEK MS (bioMérieux, Marcy-l’Étoile, France).

Antimicrobial susceptibility testing. The minimum inhibitory concentrations of 16 of 18 antibiotics, specifically piperacillin, cefazolin, cefotaxime, ceftazidime, cefepime, sulbactam/ampicillin, cefpodoxime, aztreonam, imipenem, meropenem, gentamicin, amikacin, minocycline, fosfomycin, sulfamethoxazole trimethoprim, and levofloxacin, were determined by broth microdilution on a DP31 dry plate (Eiken Chemical Co., Tokyo, Japan). The minimum inhibitory concentrations of the other two antibiotics, cefmetazole and ciprofloxacin, were determined by the agar dilution method, and the results were interpreted according to the Clinical Laboratory Standards Institute (CLSI) guidelines M100-S30. The experiment was controlled using the E. coli reference strain ATCC 25,922 for negative quality control. ESBL phenotypes were confirmed using Klebsiella pneumoniae ATCC 700603 as a positive quality control strain according to the CLSI guidelines M100-S30.

Characterization of ESBL genes, ST131 clade screening, and multi-locus sequence typing. DNA was extracted using the Cica Geneus” DNA Extraction reagent (Kanto Chemical Co., Tokyo, Japan). PCR was conducted to determine the genetic basis of resistance in ESBL-producers, targeting β-lactamase-encoding genes (blaTEM, 800 bp; blaSHV, 713 bp; blaCTX-M, 688 bp; blad/ba1-bla5, 564 bp), as previously described. The presence of blaCTX-M (band size 875 bp) was confirmed as previously described. PCR was conducted to identify blaCTX-M-14 and blaCTX-M-25 using primer sets bladCTX-M group9 (5′-ATGGTGAAAGAGAGTGCAA-3′) and bladCTX-Mgroup9 (5′-CCCTCGCGGATGTCT-3′). Amplification was carried out with an initial denaturation at 94°C for 4 min, followed by 30 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, and final extension at 72°C for 10 min. PCR could not sufficiently discriminate between blaCTX-M-14, and blaCTX-M-25, because the band sizes for both blaCTX-M-14 and blaCTX-M-25 were 870 bp and therefore Sanger sequencing was employed, and the resulting amplified DNA sequences obtained were compared with those in the repository database using the BLAST program of the National Center for Biotechnology Information to distinguish between the genes. Isolates were initially screened for ST131 strains as previously described.

Multi-locus sequence typing of all ESBL isolates was performed as described by Lai et al. Seven housekeeping genes (ade, fumC, gyrB, icd, mdh, purA, and recA) were amplified, sequenced, and an allele number was subsequently allocated according to Enterobase (https://enterobase.warwick.ac.uk/). The STs were assigned based on the allelic profiles.

Whole genome sequencing and assembly. ST131 isolates detected were subjected to whole-genome sequencing. Genomic DNA was extracted using the Nucleospin Tissue Kit (Macherey–Nagel, Düren, Germany). DNA (400 ng) was fragmented and subjected to size selection with an insert size of about 400 bp. For sequenc-
Bioinformatics and phylogenetic analysis. Assembled sequences of the 25 Ghanaian strains were aligned to the genome sequence of reference strain EC958 (accession no: HG941718). SNPs were predicted, and the alignment file was cleaned using snippy v4.6.[15] Recombinant regions were excluded using Gubbins v2.4.[16] Core genome SNPs were extracted using SNP-sites[17] and a phylogenetic tree of 25 ST131 isolates was constructed using iq-tree.[18] Pangenome analysis was performed using Roary v3.12.0.[19] To investigate these isolates within the global context, we constructed a maximum-likelihood phylogenetic tree of all 25 isolates along with a global collection of 86 isolates from a published article[20] based on 2656 core genome SNP alignment. Data on these 86 strains were obtained in December 2020. The raw reads were retrieved from GenBank and assembled with a unicycler. Assembled genomes were annotated using prokka v1.13.[21] The evolutionary puzzle of clone O25:H4-ST131 producing CTX-M-15 region of our strain EC55 using BLAST. The search produced matches with several genomes in the database. We obtained and compared the genetic environment of blaCTX-M-15 in our strains EC55 and Ec1494 to one found on plasmid pS802-CTX-M (accession no: MW495061), recovered from the database with 100% query cover and sequence identity, and visualized using Easyfig v2.2.[22] Complete and draft genome sequences have been deposited in GenBank under the Bioproject PRJNA473419. Accession numbers of all strains used in this study can be found in Supplementary data S1.

Data availability

Datasets generated during this study are available from the corresponding author upon reasonable request.

Received: 12 April 2021; Accepted: 17 January 2022
Published online: 03 February 2022

References

1. Song, J., Oh, S. S., Kim, J., Park, S. & Shin, J. Clinically relevant extended-spectrum β-lactamase-producing Escherichia coli isolates from food animals in South Korea. Front. Microbiol. 11, 604. https://doi.org/10.3389/fmicb.2020.00604 (2020).
2. Pitout, J. D., Nordmann, P., Laupland, K. B. & Poirel, L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamas (ESBLa) in the community. J. Antimicrob. Chemother. 56, 52–59. https://doi.org/10.1093/jac/dkt166 (2005).
3. Petty, N. K. et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc. Natl. Acad. Sci. USA 111, 5694–5699. https://doi.org/10.1073/pnas.1322678111 (2014).
4. Nicolau-Chanoïne, M. H. et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 61, 273–281. https://doi.org/10.1093/jac/dkm464 (2008).
5. Lai, S. H. et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J. Clin. Microbiol. 46, 1076–1080. https://doi.org/10.1128/JCM.02605-07 (2008).
6. Pitout, J. D. & DeVinney, R. Escherichia coli ST131: A multidrug-resistant clone primed for global domination. F1000Rex https://doi.org/10.12688/f1000research.10609.1 (2017).
7. Johnson, J. R. et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J. Infect. Dis. 207, 919–928. https://doi.org/10.1093/infdis/jix933 (2013).
8. Blanc, V. et al. Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b:H4 and O16:H5 ST131 strains. J. Antimicrob. Chemother. 69, 1231–1237. https://doi.org/10.1093/jac/dkt519 (2014).
9. Dalapoulou, K. et al. Detection of colistin resistance in the highly virulent Escherichia coli ST131 H30Rx clone in Greece. J. Glob. Antimicrob. Resist. 20, 31–32. https://doi.org/10.1016/j.jgar.2019.11.014 (2020).
10. Saldern, A. B. S. et al. Mcr-positive Escherichia coli ST131-H22 from poultry in Brazil. Emerg. Infect. Dis. 26, 1951–1954. https://doi.org/10.3201/eid2608.191724 (2020).
11. Gong, L. et al. A Nosocomial respiratory infection outbreak of carbapenem-resistant Escherichia coli ST131 with transmissible blaKPC-2 carrying plasmids. Front. Microbiol. 11, 2068. https://doi.org/10.3389/fmicb.2020.02068 (2020).
12. Doi, Y. et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin. Infect. Dis. 56, 641–648. https://doi.org/10.1093/cid/cis942 (2013).
13. Pitout, J. D. D. & Finn, T. J. The evolutionary puzzle of Escherichia coli ST131. Infect. Genet. Evol. 81, 104265. https://doi.org/10.1016/j.meegid.2020.104265 (2020).
14. Liu, C. M. et al. Escherichia coli ST131-H22 as foodborne uropathogen. MBio https://doi.org/10.1128/mBio.00470-18 (2018).
47. Inwezerua, C.
46. Lyimo, B.
45. Ravi, A., Valdés-Varela, L., Gueimonde, M. & Rudi, K. Transmission and persistence of IncF conjugative plasmids in the gut
15. Ben Zakour, N. L.
38. Adator, E. H.
34. Mathers, A. J., Peirano, G. & Pitout, J. D. The role of epidemic resistance plasmids and international high-risk clones in the spread
29. World Health Organization. Antimicrobial resistance: Global report on surveillance.
26. Wang, J.
19. Stoesser, N.
37. Merino, I.
24. Tagoe, D. N. A. & Attah, C. O. A Study of Antibiotic Use and Abuse in Ghana: a case study of the Cape Coast Metropolis.
66. https://doi.org/10.1093/jac/dkq415 (2011).
2012, 658470. https://doi.org/10.5402/2012/658470 (2012).
7. Seni, J. et al. The population structure of clinical extra-intestinal Escherichia coli in a teaching hospital from Nigeria. Diagn. Microbiol. Infect. Dis. 92, 46–49. https://doi.org/10.1016/j.diagmicrobio.2018.04.001 (2018).
35. Oduro-Mensah, D.
33. Wang, J. P. & Vartivarian, S. E. IncF1-based conjugative plasmid ST131-C1-M27 clade colonizing patients in Europe. J. Antimicrob. Chemother. 73, 2973–2980. https://doi.org/10.1093/jac/dkx146 (2017).
28. Bányai, K. et al. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 28, 565–591. https://doi.org/10.1128/CMR.00116-14 (2015).
5. Adator, E. H. et al. Whole genome sequencing differentiates presumptive extended spectrum beta-lactamase producing Escherichia coli along segments of the one health continuum. Microorganisms. https://doi.org/10.3390/microorganisms8030448 (2020).
37. Merino, I. et al. Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe. J. Antimicrob. Chemother. 73, 2973–2980. https://doi.org/10.1093/jac/dkx146 (2017).
15. Ben Zakour, N. L. et al. Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131. MBio 7, e01262. https://doi.org/10.1128/mBio.01262-15 (2016).
26. Wang, J.
25. Rogers, B. A., Sidjabat, H. E. & Paterson, D. L. Antibiotic resistance patterns of Escherichia coli isolated from Nigerian patients on antimicrobial resistance surveillance programs. Eur. J. Clin. Microbiol. Infect. Dis. https://doi.org/10.1007/s10096-021-04271-w (2021).
26. Wang, J.
9. Bevan, E. R., Jones, A. M. & Hawkey, P. M. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in
42. Falgenhauer, L.
26. Wang, J.
41. Bevan, E. R., Jones, A. M. & Hawkey, P. M. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in
19. Stoesser, N.
26. Wang, J.
26. Wang, J.
28. Bányai, K. et al. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 28, 565–591. https://doi.org/10.1128/CMR.00116-14 (2015).
33. Wang, J. P. & Vartivarian, S. E. IncF1-based conjugative plasmid ST131-C1-M27 clade colonizing patients in Europe. J. Antimicrob. Chemother. 73, 2973–2980. https://doi.org/10.1093/jac/dkx146 (2017).
28. Bányai, K. et al. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 28, 565–591. https://doi.org/10.1128/CMR.00116-14 (2015).
5. Adator, E. H. et al. Whole genome sequencing differentiates presumptive extended spectrum beta-lactamase producing Escherichia coli along segments of the one health continuum. Microorganisms. https://doi.org/10.3390/microorganisms8030448 (2020).
37. Merino, I. et al. Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe. J. Antimicrob. Chemother. 73, 2973–2980. https://doi.org/10.1093/jac/dkx146 (2017).
15. Ben Zakour, N. L. et al. Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131. MBio 7, e01262. https://doi.org/10.1128/mBio.01262-15 (2016).
26. Wang, J.
25. Rogers, B. A., Sidjabat, H. E. & Paterson, D. L. Antibiotic resistance patterns of Escherichia coli isolated from Nigerian patients on antimicrobial resistance surveillance programs. Eur. J. Clin. Microbiol. Infect. Dis. https://doi.org/10.1007/s10096-021-04271-w (2021).
26. Wang, J.
9. Bevan, E. R., Jones, A. M. & Hawkey, P. M. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in
19. Stoesser, N.
26. Wang, J.
26. Wang, J.
25. Rogers, B. A., Sidjabat, H. E. & Paterson, D. L. Antibiotic resistance patterns of Escherichia coli isolated from Nigerian patients on antimicrobial resistance surveillance programs. Eur. J. Clin. Microbiol. Infect. Dis. https://doi.org/10.1007/s10096-021-04271-w (2021).
26. Wang, J.
9. Bevan, E. R., Jones, A. M. & Hawkey, P. M. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in
Acknowledgements
Our utmost appreciation goes to the staff of Effia Nkwanta Regional Hospital and Tamale Teaching Hospital for their immense support.

Author contributions
A.Ab. and R.S. designed the experiments. S.M., W.S., A.Ay., and I.P. performed the experiments and analyzed the data. R.S., T.H., S.I., and T.S. organized the funding. A.Ab. and R.S. supervised the study. S.M. and R.S. wrote the original draft of the manuscript. All authors read and approved the final manuscript.

Funding
This research work was funded by the Japan Agency for Medical Research and Development (AMED, http://www.amed.go.jp/en/) under Grant Numbers JP19fm0108010 and 20wm0125007 (TH, TS, SI, RS), 20wm0225013 (TS, RS), and the Ohyama Health Foundation (RS). The funders had no role in the study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-05869-6.

Correspondence and requests for materials should be addressed to A.A. or R.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022